COMPANY

Enveda Biosciences

HQ: Boulder, CO source · enveda.com ↗ · Mountain

7 open jobs · last seen Oct 23, 2026 · 3 sources

Keywords: small molecule metabolic

Location: Boulder, CO · source · Oct 15, 2026

Profile checked Oct 10, 2026

Hiring

Title	Location (from posting)	Employer posted	First seen
VP, Clinical Biostatistics	Remote, United States	Oct 9, 2026	Oct 11, 2026
Senior Histopathologist	Hyderabad	Sep 28, 2026	Oct 11, 2026
Director, ADME	Hyderabad	Sep 4, 2026	Oct 11, 2026
Assoc. Director, Medicinal Chemistry	Hyderabad	Aug 10, 2026	Oct 11, 2026
Research Associate, Invivo Pharmacology	Hyderabad	Aug 7, 2026	Oct 20, 2026

See all 7 jobs

Raises and deals from press releases

Raise Series E · $311M · announced Sep 23, 2026 Company release ↗
Source quote
- Sep 23, 2026 · Company release ↗
  “BOULDER, Colo. — ( BUSINESS WIRE ) — September 23, 2026: Enveda, a clinical-stage biotechnology company that uses AI to discover medicines from life’s chemistry, today announced the close of a $311 million Series E financing led by Catalio Capital Management”
Raise Series D · $150M · announced Sep 4, 2025 Company release ↗
Source quote
- Sep 4, 2025 · Company release ↗
  “Enveda Raises $150M Series D Funding to Reach Unicorn Status”
Raise Series C · $130M · announced Nov 21, 2024 Company release ↗
Source quote
- Nov 21, 2024 · Company release ↗
  “Enveda Closes $130M Series C Funding to Deliver Multiple Clinical Readouts from a Pipeline of 10 Development Candidates Enveda”
Raise Series B · $55M · announced Jun 14, 2024 Company release ↗
Source quote
- Jun 14, 2024 · Company release ↗
  “Enveda Biosciences Announces $55M in New Funding to Accelerate Platform and Advance Multiple Candidates to Clinical Trials BOULDER, Colo.–( BUSINESS WIRE )–Enveda Biosciences (“Enveda”), a biotechnology company using AI to translate nature into new medicines, announced today a new financing round”

Raises announced in these releases: $646M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

Sep 23, 2026 Raise Series E · $311M source ↗
Sep 4, 2025 Raise Private equity round — Series D: $150M (total, as published), announced Sep 4, 2025. Source: company's own press page. source ↗
Sep 4, 2025 Raise Series D · $150M source ↗
Feb 26, 2025 Raise Private equity round — Series C: $150M (total, as published), announced Feb 26, 2025. Source: company's own press page. source ↗
Nov 21, 2024 Raise Private equity round — Series C: $130M (total, as published), announced Nov 21, 2024. Source: company's own press page. source ↗
Nov 21, 2024 Raise Series C · $130M source ↗
Jun 14, 2024 Raise Series B · $55M source ↗

Funding

Raised: $430.0M. Last 2 years.

Sep 4, 2025 Private equity round — Series D: $150M (total, as published), announced Sep 4, 2025. Source: company's own press page. source ↗
Feb 26, 2025 Private equity round — Series C: $150M (total, as published), announced Feb 26, 2025. Source: company's own press page. source ↗
Nov 21, 2024 Private equity round — Series C: $130M (total, as published), announced Nov 21, 2024. Source: company's own press page. source ↗

Open jobs 7

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
VP, Clinical Biostatistics	Remote, United States	Oct 9, 2026	Oct 11, 2026	Executive
Senior Histopathologist	Hyderabad	Sep 28, 2026	Oct 11, 2026	Senior
Director, ADME	Hyderabad	Sep 4, 2026	Oct 11, 2026	Senior
Assoc. Director, Medicinal Chemistry	Hyderabad	Aug 10, 2026	Oct 11, 2026	Senior
Research Associate, Invivo Pharmacology	Hyderabad	Aug 7, 2026	Oct 20, 2026	Not stated
Senior Research Associate, Invivo Pharmacology	Hyderabad	May 12, 2026	Oct 12, 2026	Senior
Asst. VP, Medicinal Chemistry	Hyderabad	Apr 12, 2024	Oct 11, 2026	Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.